Board of Directors

Cam Gallagher has more than 30 years of experience in the life science and biotech industry with a focus on new company formation, corporate development, marketing, operations, and early-stage investing. Mr. Gallagher has served as a member of the Ocuphire (now Opus) Board since January 2019 and Chair since December 2019. He was previously co-founder and board member of Zentalis Pharmaceuticals (Nasdaq: ZNTL) from December 2014 to November 2024. He also served as President of Zentalis from May 2022 to November 2024. He also currently serves on the board of directors of SelectION and Immuosft. He was previously a founding board member at VelosBio, which was acquired by Merck in 2020. Prior to joining Zentalis as President, he was a Director and Chief Business Officer at RetroSense Therapeutics, which was acquired by Allergan in 2016. Mr. Gallagher was Managing Director of Nerveda, LLC, a life science seed fund he co-founded in June 2007. Prior to these roles, he held management positions at Oncternal, Zavante, Verus Pharma, CV Therapeutics and Dura Pharma. Mr. Gallagher holds an M.B.A. from the University of San Diego and a B.S. in Business Administration from Ohio University.